Statins offer 30% lower risk of COPD exacerbation
A new retrospective case-control study among patients with chronic obstructive pulmonary disease (COPD) found a 30% decreased risk of COPD exacerbation with any statin use.
A new retrospective case-control study among patients with chronic obstructive pulmonary disease (COPD) found a 30% decreased risk of COPD exacerbation with any statin use.
The study published in the July 2013, issue of the American Journal of Medicine, was led by M.T. Wang from the School of Pharmacy at the National Defense Medical Center in Taipei, Taiwan. “Statin use was associated with a reduced risk of COPD exacerbation, with a future risk reduction for statins prescribed more recently or at high doses,” Wang wrote.
This is the first study to examine the recency and duration effect of statin use on the risk of COPD exacerbations, according to the researchers.
Using a national health insurance claims database in Taiwan, the researchers reviewed the medical history of more than 14,300 COPD patients. They found that current use of statins was associated with a greater reduced risk of COPD exacerbation (adjusted odds ratio of .60). The protective effect of statins on COPD exacerbations is more profound for statins used for six months, or for statins prescribed at medium or high average daily dose, the researchers found. Still, the reduced risk remained significant for either short or long duration of statin use.
Remote Care Advancement for Heart Failure, COPD and Diabetes Patients
February 24th 2021In this week's episode of Tuning In to the C-Suite podcast, MHE's Briana Contreras spoke with Dr. Rob Kowal, chief medical officer of the Cardiac Rhythm and Heart Failure division at Medtronic. The two discussed how remote monitoring and IoT is changing healthcare and how remote technology is also gaining a wide-spread adoption to monitor patients at home who have chronic conditions like heart failure, chronic obstructive pulmonary disease and diabetes.
Listen
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
